




Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com



REVIEW

The ubiquitin–proteasome system: A potential target for the MASLD

Yue Liu^a, Meijia Qian^{a,b}, Yonghao Li^a, Xin Dong^c, Yulian Wu^c,
Tao Yuan^a, Jian Ma^d, Bo Yang^{a,e}, Hong Zhu^{a,f,g,*}, Qiaojun He^{a,c,*}

^aInstitute of Pharmacology & Toxicology, Zhejiang Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

^bHangzhou Zhongmei Huadong Pharmaceut Co., Ltd., Hangzhou 310011, China

^cSecond Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China

^dCenter for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

^eSchool of Medicine, Hangzhou City University, Hangzhou 310015, China

^fEngineering Research Center of Innovative Anticancer Drugs, Ministry of Education, Hangzhou 310058, China

^gInnovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310058, China

Received 14 June 2024; received in revised form 20 September 2024; accepted 20 December 2024

KEY WORDS

MASLD;
Ubiquitin proteasome
system (UPS);
Ubiquitination;
E3 ubiquitin ligase;
Deubiquitinase (DUB);
SUMOylation;
Neddylation;
Therapeutic targets

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD), the most prevalent chronic liver condition globally, lacks adequate and effective therapeutic remedies in clinical practice. Recent studies have increasingly highlighted the close connection between the ubiquitin–proteasome system (UPS) and the progression of MASLD. This relationship is crucial for understanding the disease's underlying mechanism. As a sophisticated process, the UPS govern protein stability and function, maintaining protein homeostasis, thus influencing a multitude of elements and biological events of eukaryotic cells. It comprises four enzyme families, namely, ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), ubiquitin-protein ligases (E3), and deubiquitinating enzymes (DUBs). This review aims to delve into the array of pathways and therapeutic targets implicated in the ubiquitination within the pathogenesis of MASLD. Therefore, this review unveils the role of ubiquitination in MASLD while spotlighting potential therapeutic targets within the context of this disease.

© 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Corresponding authors.

E-mail addresses: hongzhu@zju.edu.cn (Hong Zhu), qiaojunhe@zju.edu.cn (Qiaojun He).

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apsb.2025.01.010>

2211-3835 © 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) is recognized as the predominant chronic liver condition globally, affecting approximately 38% of the population^{1,2}. To reflect the pathology and etiology of these conditions more accurately, metabolic dysfunction-associated steatotic liver disease (MASLD) was put forward to replace the term NAFLD, defined by the cases with hepatic steatosis and at least one—and only one—of the five cardiometabolic risk factors³. MASLD encompasses a spectrum of liver diseases, including simple steatosis (NAFL) and nonalcoholic steatohepatitis (MASH), and MASLD is commonly associated with metabolic disorders including obesity, dyslipidemia, type 2 diabetes, and metabolic syndrome^{4,5}. Given the complex pathogenesis of MASLD, substantial effort has been put into exploring novel therapeutic targets. Presently, the most promising targets include cellular mechanisms of death and metabolism, inflammatory processes, interaction between intestine and liver, and direct inhibition of fibroblast activation and extracellular matrix deposition⁶. Despite these efforts, limited therapeutic agents have been officially approved for MASLD treatment.

Accumulating evidence suggested that the ubiquitin-proteasome system (UPS) plays a pivotal role in MASLD pathogenesis, serving as the primary mechanism for protein degradation in eukaryotic cells. It influences various cellular processes including DNA repair, stress response, and cell proliferation⁷. The system consists of ubiquitin, the 26S proteasome, and several

enzymes such as E1, E2, E3, and deubiquitinases. The ubiquitin binding to the substrate is carried out through a multi-step cascade composed of E1, E2, and E3 enzymes. The UPS operates through a sequence of steps beginning with the attachment of ubiquitin's carboxyl group to the sulfhydryl group of the ubiquitin-activating enzymes (E1), forming a thioester bond. This activated ubiquitin is then transferred to ubiquitin-conjugating enzymes (E2s), and subsequently, ubiquitin ligase enzymes (E3s) collaborate with charged E2s to attach the ubiquitin to the substrate. The ubiquitinated substrates are eventually recognized by proteasomes and finally decomposed into short peptides or amino acids under the catalysis of proteases^{8–10}. In addition, SUMOylation and NEDDylation modifications are two common ubiquitin-like modifications that generally affect protein function or stability and also play a regulatory role in MASLD progression (Fig. 1). As UPS plays a crucial role in the progression of chronic liver disease by regulating protein degradation, it may serve as a potential targeted therapeutic strategy for MASLD^{11,12} (Fig. 2).

2. E3 ubiquitin ligase and MASLD

Since E3 ligases are responsible for binding to substrates and determining the specificity of the ubiquitin system, there are a large number of E3 ligases in different organisms, but only a few E1 and E2 enzymes^{13,14}. Based on their structure and function, E3 ligases can be classified into several types: Ring finger type,




Figure 1 Ubiquitination and ubiquitin-like modification processes. (A) UPS system associated enzymes E1 (ubiquitin activating enzyme), E2 (ubiquitin-conjugating enzyme), E3 (ubiquitin ligase enzymes) and DUB (deubiquitinases) at different steps and the corresponding fate of the substrate. Biochemical process of SUMOylation (B) and NEDDylation (C). SUMOylation process is catalyzed by E1 activating enzymes (including SAE1 and SAE2), E2 binding enzyme UBC9 and SUMO E3 ligase. SENPs can catalyze the removal of SUMO from the substrate. The NEDDylation process is catalyzed by a cascade of NEDD8-activating enzyme (NAE), NEDD8 binding enzyme (UBE2M/UBE2L or UBE2F), and NEDD8 ligase.

Table 1 Classification of E3 ubiquitin ligases.

Category	Subclass	Representative member	structural features	Mechanism of action
Single-subunit E3s	RING	MDM2 RNF4	RING domain or U-box domain	Directly interacting with E2 ubiquitin-conjugating enzymes to catalyze ubiquitin transfer
	HETC	Itch Smurf1	HECT domain	Two-step reaction (first forming a thioester bond with ubiquitin, then transferring it to the substrate)
	RBR	ARIH1 PARKIN	Two RING domains and an IBR domain	Two-step reaction
Multi-subunit E3s	SCF		SKP1, CUL1, RBX1, and a variable F-box protein	F-box protein recognizes the substrate
	CUL3-BTB		CUL3, RBX1, and BTB proteins	BTB protein recognizes the substrate
	CUL4-DDB1-DWD		CUL4, DDB1, RBX1, and a variable DWD protein	DWD protein recognizes the substrate
	APC/C		The catalytic core, the platform and the tetratricopeptide repeat (TPR) lobe	

Table 2 Pathophysiological roles of E3 ubiquitin ligases in MASLD.

Name	Expression in MASLD	Inhibit/Promote MASLD	Direct target	Ubiquitin chain types	Ref.
TRIM16	Increase	Inhibit	P-TAK1	K48	15
TRIM31	Decrease	Inhibit	RHBDF2/MAP3K7	K48/K48	16,17
TRIM28	—	Inhibit	FASN	K48	18
TRIM37	—	Inhibit	—	—	19
TRIM38	Decrease	Inhibit	TAB2	—	20
TRIM26	Decrease	Inhibit	C/EBP δ	—	21
TRIM72	Increase	Inhibit	—	—	22
TRAF5	Decrease	Inhibit	JNK1	—	23
RNF13	Increase	Inhibit	STING	—	24
SH3RF2	Decrease	Inhibit	ATP citrate lyase	K48	25
RNF5	Decrease	Inhibit	HRD1	K48 & K33	26
HRD1	Decrease	Inhibit	ACLY	—	27
Gp78	—	Inhibit	SREBP1	—	28
Ubr1	—	Inhibit	Plin2	—	29
TRIM67	Increase	Promote	—	—	30
TRIM59	Increase	Promote	GPX4	—	31
TRAF3	Increase	Promote	TAK1	—	32
TRAF6	—	Promote	ASK1	K63	33
MKRN1	—	Promote	AMPK α	K48	34
Grail	Increase	Promote	Sirtuin 1	K48	35
FBXW5	—	Promote	ASK1	K63	36
FBXW7	Decrease	Promote	PPAR α /ERR α	—	37
		Inhibit	HMGB1	—	38
Smurf1	Increase	Inhibit	PPAR γ	K63	39
		Promote	SREBP-1c	—	40

facilitates the transfer of activated ubiquitin from the E2 enzyme to the substrate protein without directly binding to ubiquitin molecules⁴¹. The members of the tripartite motif (TRIM) and the tumor necrosis factor (TNF) receptor-associated factor (TRAF) family subfamilies are important members of the RING E3 family and there is ample evidence indicating that the two subfamilies, as well as other members, play significant roles in regulating the pathogenesis of MASLD.

2.1.1. The TRIM family

TRIM family are distinguished by an N-terminal tripartite RBCC motif that includes one or two BBox domains, a coiled-coil (CC) domain, and a RING-finger domain. The human genome encodes over 70 TRIM family members in humans, which are categorized into 11 subgroups based on their domain architecture⁴².

TRIM16 has been shown to reduce lipid accumulation and inflammation in a MASH mouse model by degrading phosphorylated

transforming growth factor- β activated kinase 1 (TAK1) and activating the mitogen-activated protein kinase (MAPK) signaling pathway¹⁵. Moreover, separate studies have demonstrated that TRIM31 reduces MASLD by promoting the proteasomal degradation of rhomboid 5 homolog 2 (RHBDF2) and mitogen-activated protein kinase kinase 7 (MAP3K7)^{16,17}.

TRIM28 and TRIM37 are also noted for their protective effects in experimental MASH. Knockout of TRIM37 in mice results in mulibrey nanism, characterized by prenatal-onset growth failure, an increased risk for tumors, fatty liver, and type 2 diabetes¹⁹. Liver-specific KRAB-associated protein 1 (KAP1, also known as TRIM28), leads to sexually dimorphic phenotypic fatty acid synthase (FASN) shown that sorting nexin 8 (SNX8) could recruit TRIM28 to promote the ubiquitination and degradation of FASN, the rate-limiting enzyme in fatty acid synthesis¹⁸. Additionally, depletion of TRIM38 in mice exacerbates liver inflammation and fibrosis induced by a high-fat and high-cholesterol diet. Mechanistically, TRIM38 enhances the ubiquitination and degradation of transforming growth factor- β -activated kinase 1 binding protein 2 (TAB2) and suppresses the MAPK signaling cascades²⁰. TRIM26 also plays a role in preventing the progression of steatohepatitis by inhibiting the activation of C/EBP δ signaling²¹.

Conversely, there are also several studies showing that TRIM family members exacerbate the progression of MASLD. Specifically, TRIM67 protein levels are elevated in obese conditions, which enhances inflammation and facilitates the development of MASLD. This effect is linked to interactions with peroxisome proliferator-activated receptor- γ coactivator (PGC)-1 α , a transcription coactivator crucial for regulating metabolic processes³⁰. Additionally, TRIM59 has been shown to induce both ferroptosis and steatosis by interacting with glutathione peroxidase 4 (GPX4) and promoting its ubiquitination, highlighting a novel mechanism by which TRIM59 contributes to MASLD pathology³¹. Moreover, TRIM72 plays a pivotal role in insulin resistance, a key component of metabolic syndrome associated with MASLD. It mediates insulin resistance by accelerating the degradation of insulin receptor substrates (IRS and IRS1) in cardiac and skeletal muscle tissues, with its expression markedly increased in these conditions. Intriguingly, physical exercise has been found to enhance muscle insulin sensitivity through the TRIM72/PI3K/Akt/mTOR signaling pathway, offering a potential therapeutic avenue²².

2.1.2. The TRAF family

The TRAF family includes seven characterized members, six of which, with the exception of TRAF1, possess a RING finger domain enabling their function as ubiquitin ligases. Notably, several TRAF family members have been implicated in the pathogenesis of MASLD, through their E3 ligase activities or involvement in inflammatory signaling pathways.

TRAF2 is instrumental in the activation of several downstream pathways, including the canonical and noncanonical nuclear factor kappa B (NF- κ B) and c-Jun N-terminal kinase (JNK) cascades. A study has shown that TRAF2 depletion in hepatocytes inhibits glucagon-mediated liver gluconeogenesis in high-fat diet (HFD) mice, although it does not affect insulin sensitivity⁴³. This suggests that hepatic TRAF2 acts as a positive regulator of glucagon signaling and hepatic gluconeogenesis in states of overnutrition. Conversely, TRAF3 in hepatocytes enhances the activation of TAK1 through increased ubiquitination and phosphorylation, promoting liver steatosis and insulin resistance³². TRAF6 meanwhile, mediates Lys6-associated polyubiquitination of apoptosis signal-regulating

kinase 1 (ASK1), activating ASK1 and facilitating the progression of MASH³³. In contrast, TRAF5 serves as a negative regulator of hepatic steatosis and suppresses JNK1 activity, demonstrating its protective role against hepatic lipid accumulation²³.

2.1.3. Others

Ring finger protein 13 (RNF13) interacted with the stimulator of interferon genes protein (STING) and facilitated its proteasomal degradation, eventually inhibiting liver lipid accumulation²⁴. Makorin ring finger protein 1 (MKRN1) promotes the ubiquitination and degradation of adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) and then promotes MASLD, insulin resistance, and obesity associated with HFD³⁴. Grail regulates the lipid accumulation in hepatic steatosis *via* interacting with sirtuin type 1 (Sirt1)³⁵. SH3 domain containing ring finger 2 (SH3RF2) can promote K48 ubiquitination modification of ATP citrate lyase and promote its ubiquitin-dependent degradation. Hepatocyte SH3RF2 deficiency would aggravate MASLD²⁵. Both HMG-CoA reductase degradation 1 (HRD1) and RNF5 were endoplasmic reticulum localized in cells. HRD1 down-regulates the protein level of ATP citrate lyase (ACLY), a key enzyme regulating lipogenesis, thus alleviating MASLD in *db/db* mice²⁷. RNF5 directly binds to HRD1 and promotes its K48 and K33-linked ubiquitination, then diminishes the palmitic acid and oleic acid (PAOA) lipid deposition²⁶. Autocrine motility factor receptor (AMFR, also known as Gp78), a member of RING-H2 E3 ubiquitin ligases, has a Ring finger domain, CUE motif, and E2 binding site⁴⁴. Studies have shown that Gp78 plays a protective role in MASLD and knockout of Gp78 up-regulates unfolded protein response and sterol regulatory element-binding protein 1 (SREBP-1) to increase lipid accumulation²⁸. Studies have shown that nutrient could affect the activity of certain E3 ubiquitin ligases, thus affecting the progression of MASLD. Leucine and isoleucine bind to ubiquitin protein ligase E3 component N-recognin 1 (UBR1) and induce its activation, and UBR1 promotes the degradation of perilipin 2 (PLIN2) to ameliorate hepatic steatosis²⁹.

2.2. SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase

SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase is the largest family of ubiquitin ligases. Among its members, F-box and WD repeat domain containing 7 (FBXW7) and F-box and WD repeat domain containing 5 (FBXW5) have shown substantial relevance to MASLD. The role of FBXW7 in lipid metabolism remains ambiguous; however, its function in MASLD has garnered considerable attention due to its regulatory impact on several metabolic transcription factors, including SREBP1/2, the nuclear receptors nuclear receptor subfamily 1, group D member 2 (REV-ERB α , also known as NR1D1), estrogen-related receptor alpha (ERR α , also known as NR3B1), and the co-regulator proteins nuclear receptor coactivator 3 (NCOA3) and PGC-1 α ⁴⁵⁻⁴⁷. A recent study indicates that decreased expression of FBXW7 is a feature of advanced MASH; as FBXW7 regulates the transcription activity of the nutrient-sensing nuclear receptors peroxisome proliferator-activated receptor α (PPAR α) and ERR α , thus promoting the progress of MASH³⁷. Additionally, FBXW7 ameliorates hepatic inflammation and insulin resistance by diminishing high mobility group box 1 (HMGB1)-mediated innate immune signaling³⁸. On the other hand, FBXW5 exacerbates nonalcoholic steatohepatitis by facilitating the addition of Lys63-linked ubiquitin to ASK1, suggesting that drug candidates mimicking FBXW5(S1) or FBXW5(S3) might be viable therapeutic approaches for MASH³⁶.

Furthermore, CUL4B-DDB1 also plays a role in the development of MASLD. The pancreatic progenitor cell differentiation and proliferation factor (PPDPF) impedes the interaction between Raptor and its E3 ligase CUL4B-DDB1, thereby inhibiting the ubiquitination and activation of Raptor, which results in suppression of the mTORC1–S6K–SREBP1 signaling pathway⁴⁸.

2.3. HECT E3 ubiquitin ligases

HECT E3s are classified into 3 groups: the Nedd4 family, the HERC family and others¹⁴. Within the NEDD4 family, smad ubiquitin regulatory factor 1 (SMURF1) promotes K63-linked polyubiquitination of PPAR γ , thereby inhibiting its transcriptional activity and reducing the lipid accumulation in the liver⁴⁹. However, another study has shown that SMURF1 might aggravate lipid accumulation in the liver by stabilizing SREBP-1c in an E3 activity-independent in the late phases of MASLD⁴⁰. This highlights the diverse regulatory roles that HECT E3 ligases play in hepatic lipid metabolism and provides insights into potential therapeutic targets for treating liver diseases.

3. Deubiquitinases (DUBs) and MASLD

Ubiquitination represents a reversible post-translational modification process, where DUBs catalyze the removal of ubiquitin moieties from target proteins or polyubiquitin chains. This results in modifications to the function or stability of these targeted proteins⁵⁰. Based on sequence and domain conservation, seven structurally distinct DUB families have been proposed: the ubiquitin-specific proteases (USPs), the ovarian-tumor proteases (OTUs), the ubiquitin C-terminal hydrolases (UCHs), Machado–Joseph disease protein domain proteases (MJDs), JAMM/MPN domain-associated metallopeptidases (JAMMs), motif interacting with ubiquitin-containing novel DUB family proteases (MINDYs) and zinc finger-containing ubiquitin peptidase 1 (ZUP1)^{50–52}. Amongst them, several DUBs have been pinpointed as exerting vital roles in the regulation of cell cycle control, cell signaling, and apoptosis.

Some DUBs have also been reported to be involved in the regulation of MASLD. In the sections that follow, we will outline these DUBs and present examples illustrating their roles in the onset and progression of MASLD (Table 3^{53–70}).

3.1. The ubiquitin-specific proteases (USPs)

The USP class constitutes the majority of the DUBs, due to a rapid diversification during evolution, possibly in concert with the diversification of E3 ligases⁵¹. These proteases comprise three subdomains, analogized to the fingers, thumb and palm of a right hand. Most USPs contain a core catalytic domain with insertions and terminal extensions bearing additional protein interaction domains^{8,71}.

Several studies have shown that USPs play a protective role in MASLD. For example, cylindromatosis-associated DUB (CYLD) functions as a pivotal suppressor in MASLD and relates to metabolic disorders⁵³. Mechanistically, hepatocyte CYLD directly interacts with and deubiquitinates TAK1 and suppresses the downstream NF- κ B and JNK cascades. Hepatic steatosis was ameliorated in Hepatocyte-specific CYLD transgenic mice but worsened in hepatocyte-specific CYLD-KO mice⁵³. Moreover, USP4 and USP18 also deubiquitinate TAK1 and inhibit TAK1 activation^{54,56}. In addition to this, USP4 also deubiquitinates and stabilizes PPAR α . Oxidized fish oil (OFO) induced the decline of USP4 protein expression, promoting oxidative stress and inducing mitochondrial dysfunction and lipotoxicity⁵⁵.

Inactive rhomboid protein 2 (IRHOM2) was a crucial and positive regulator of inflammation-associated diseases and hepatocyte USP13 interacted with IRHOM2 and removed its K63-linked ubiquitination in response to metabolic stresses. When USP13 is knocked out in hepatocytes, liver metabolic homeostasis is disrupted, leading to carbohydrate metabolism disorder, lipid deposition, increased inflammation, and eventually promoting MASH development⁵⁷.

Likewise, USP10 has been reported to play a protective role in the pathogenesis of MASLD through multiple mechanisms^{58,72,73}.

Table 3 Pathophysiological roles of deubiquitinases in MASLD.

Name	Expression in MASLD	Inhibit/Promote MASLD	Direct target	Regulating effect	Ubiquitin chain types	Ref.
CYLD	Decrease	Inhibit	TAK1	Activity ↓	K63	53
USP4	Decrease	Inhibit	TAK1	Activity ↓	—	54
		Inhibit	PPAR α	Degradation ↓	—	55
USP18	Decrease	Inhibit	TAK1	Activity ↓	—	56
USP13	Decrease	Inhibit	IRHOM2	Activity ↓	K63	57
USP10	Decrease	Inhibit	Sirtuin 6	Degradation ↓	—	58
USP19	—	Inhibit	—	—	—	5
OTUD3	—	Inhibit	PPAR δ	Degradation ↓	—	59
OTUB1	Decrease	Inhibit	TRAF6	Activity ↓	K63	33
TNFAIP3	Increase	Inhibit	ASK1	Activity ↓	K63/K29/K11	60
OUTLIN	—	Inhibit	—	—	—	61
USP14	Increase	Promote	FASN	Degradation ↓	—	62
USP20	—	Promote	HMGCR	Degradation ↓	—	63
USP15	Increase	Promote	FABP4&perilipins	Degradation ↓	—	64
USP11	Increase	Promote	KLF4	Degradation ↑	K63	65
USP22	—	Inhibit	Sirt1	Degradation ↓	—	66
	—	Promote	PPAR γ	Degradation ↓	K48	67
USP7	—	Promote	ZNF638	—	—	68
	—	Inhibit	IRS1	Degradation ↓	—	69
	—	Inhibit	Sirt7	Activity ↓	K63	70

USP10 manages hepatic steatosis by interacting with Sirt6, a negative regulator of inflammation and lipid metabolism, thereby removing its ubiquitin chain and ultimately preventing its degradation⁵⁸. The other study has indicated that USP10 could promote autophagy flux and activate the mTOR/Beclin1 signaling pathways in MCDD-fed mice, reducing histological steatosis, inflammation and fibrosis. Moreover, the autophagy inhibitors, chloroquine or 3-methyladenine, could reduce the suppressive effects of USP10 against steatosis. Thus, USP10 also alleviated hepatic steatosis in an autophagy-dependent manner^{72,73}.

Several other members of the USP family have been found to promote MASLD development. Both USP2 and USP14 interacted with and stabilized FASN, an essential enzyme for the conversion of dietary carbohydrates to fatty acids^{62,74}. Therefore, USP2 and USP14 are regarded to contribute to MASLD progression. USP20 stabilizes HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the cholesterol biosynthetic pathway, and USP20 was phosphorylated by mTORC1 at S132 and S134⁶³. Genetic deletion or pharmacological inhibition of USP20 markedly decreased body weight, reduced lipid deposition in the liver, and improved insulin sensitivity⁶³. USP15 deubiquitinates and stabilizes fatty acid-binding proteins (FABPs) and perilipins. FABPs are involved in the uptake of long-chain fatty acids and further metabolism, while perilipins are associated with the surface of lipid droplets and control lipid accumulation and inflammation⁶⁴. Therefore, USP15 exerts both pro-inflammatory and pro-lipid accumulation functions in MASLD, indicating its potential as a target for MASLD treatment. Furthermore, *Usp19*-null mice displayed increased glucose tolerance and insulin sensitivity with HFD fed⁵. This suggests therapeutic potential of USP19 for MASLD treatment. USP11 promoted kruppel-like factor 4 (KLF4) instability by deubiquitinating KLF4. Studies have shown that KLF4 level was down-regulated and USP11 level was up-regulated in free fatty acid (FFA)-treated cells. USP11 enhanced hepatic steatosis through KLF4 inhibition⁶⁵.

The effect of USP22 on MASLD has been found to be contradictory^{66,67}. High expression of USP22 has been associated with abnormal lipid metabolism, promoting lipid accumulation and tumorigenesis in hepatocellular carcinoma (HCC) cells. This is thought to be due to USP22's role in increasing acetyl-CoA carboxylase (ACC) and ACLY expression via the deubiquitination and stabilization of PPAR γ ⁶⁷. However, a different study has shown that USP22 could reduce lipid accumulation in the liver by modifying mitochondrial respiration in the late phases of MASLD⁶⁶. The G α 12-signaling pathway regulating SIRT1 and PPAR α appears to be responsible for these effects, as it stabilizes SIRT1 protein *via* the transcriptional induction of USP22 through increased hypoxia inducible factor 1 subunit α (HIF-1 α)⁶⁶. Further studies were required to elucidate the different mechanisms of USP22 on lipid synthesis.

Another important member of USPs, USP7, is also found to demonstrate the dual roles in MASLD. Under hypoxic conditions, PARP1-mediated poly ADP-ribosylation (PARylation) of HIF-1 α is increased by spindle and kinetochore-associated complex subunit 3 (SKA3), leading to a greater association between HIF-1 α and USP7 and hence preventing the degradation of HIF-1 α and promoting fatty acid synthesis⁷⁵. However, this work was studied for cholangiocarcinoma, and whether the findings are consistent in liver tissue still remains unknown. Zinc finger protein 638 (ZNF638) can increase the cleavage of SREBP1C, hence promoting *de novo* lipogenesis (DNL). USP7 was found to not only interact with and deubiquitylate ZNF638, but also to support the

transcription of ZNF638 *via* the stabilization of cAMP-responsive element binding protein (CREB)⁶⁸. USP7 inhibitor significantly inhibited lipid accumulation in fructose-induced hepatic steatosis⁶⁸. However, on the other hand, USP7 has been showing that could deubiquitinate IRS1 and prevent its proteasomal degradation. Deleting phosphate inorganic transporter 1 (PiT1/SLC20A1) inhibited the disassociation of USP7/IRS1 upon insulin stimulation. Hepatocyte-specific *Pit1*-KO protects against obesity induced by a high-fat diet⁶⁹. This study suggests that USP7 may inhibit the development of MASLD. Also, it was shown that USP7 suppressed the forkhead box O1 (*FOXO1*) transcriptional activity and negatively regulated SIRT7 deacetylase activity, thereby attenuating hepatic gluconeogenesis^{70,76}. Further studies are required to elucidate these various, and at times contradicting actions of USP22 and USP7 on lipid synthesis and MASLD.

3.2. The ovarian-tumor proteases (OTUs)

OTUs are a type of deubiquitinase enzyme family comprising 16 members. OTU deubiquitinase 3 (OTUD3) regulated a series of genes involved in glucose and lipid metabolism and oxidative phosphorylation by stabilizing PPAR δ . It has been found that OTUD3 knockout mice are predisposed to obesity and metabolic diseases⁵⁹. As for ovarian tumor associated proteinase B1 (OTUB1), the first identified member of OTUs, it has been found to play a suppressive role in MASH. This is thought to occur through its capacity to deubiquitinate TRAF6 thereby inhibiting the TRAF6-mediated ASK1 activation³³. As such, targeting the OTUB1–TRAF6–ASK1 axis could be a promising therapeutic approach for MASH³³. Another member of the OTUs family, tumor necrosis factor- α induced protein (TNFAIP, also known as A20), has been recognized to be a potent anti-inflammatory molecule that inhibits ASK1's polyubiquitination in hepatocytes, thus preventing the onset and progression of MASH⁶⁰. OTU deubiquitinase with linear linkage specificity (OTULIN) was a deubiquitinase involved in the regulation of inflammation, a deficiency of OTULIN in liver parenchymal cells causes steatohepatitis in mice⁶¹. Further research is required to explore the roles played by the OTUs family in MASLD. Already numerous members have been identified to be involved in inflammatory processes⁷⁷, yet much remains to be uncovered.

4. SUMOylation and MASLD

The small ubiquitin-like modifier (SUMO) family is a newly discovered ubiquitin-like molecule⁷⁸. Currently, at least six SUMO isoforms have been found, including SUMO1, SUMO2, SUMO3, SUMO4, SUMO5 and the newly discovered SUMO7. Among them, SUMO2 and SUMO3 have high homology, and they are often referred to as SUMO-2/3. SUMO2/3 and SUMO1 share only 45% homology. SUMO modification of proteins is very similar to ubiquitination modification, involving a total of three enzymatic reactions: The C-terminal of SUMO is activated ATP-dependent by the E1 activating enzyme (including SEA1 and SEA2) and subsequently transferred to the E2 binding enzyme UBC9 to form E2-SUMO thioester, which is eventually recruited by the SUMO E3 ligase to form complexes with substrates to increase specificity. However, the E2 enzyme also has the function of recognizing substrates in the absence of E3 ligase. SUMO/sentrin-specific proteases (SENPs) can catalyze the removal of SUMO from the target protein linked to SUMO and some

members of this family also participate in the maturation and activation process of SUMO.

SUMOylation is a reversible post-translational modification, as a series of proteases can remove SUMO terminal glycine from the lysine residues of the target protein. These proteases can be classified into three families based on their different subcellular localizations and substrates. The first family includes SENP1 and SENP2, which act on all members of the SUMO family. The second family comprises SENP3 and SENP5, which exert more powerful regulation on SUMO2/3. Furthermore, SENP6 and SENP7 have a similar substrate bias to SENP3 and SENP5. Several studies have reported that the SENP family plays a vital role in the progression of MASLD (Table 4^{79–81,83–86,89,90,93,94}).

Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is implicated in cell death and inflammation in the progression of MASH. SENP1 catalyzes the deSUMOylation of RIPK1, which inhibits its activation⁷⁹. SENP1 is significantly down-regulated in the livers with MASLD or MASH; and liver specific knockout of SENP1 mice will spontaneously form MASH-related phenotypes including liver inflammation, lipid accumulation, liver damage, and fibrosis⁷⁹. Mechanistically, in SENP1-deficient cells, RIPK1 is SUMOylated by protein inhibitor of activated STAT 1 (PIAS1) which alters its ubiquitination and promotes its activation. Additionally, SENP1 can de-SUMOylate Sharp-1, a repressor for PPAR γ transcription and adipogenesis, thereby promoting adipocyte differentiation and enhancing adipogenesis⁸⁰. SENP2 and lipid metabolism have been well reported. SENP2 was the most significantly increased SENP in HFD-induced fatty liver and SENP2 deficiency in the liver protects against HFD-induced metabolic disorders and hepatic steatosis⁸¹. Further research revealed that hepatic SENP2 governed the homeostasis of both liver and adipose tissues, implicating SENP2 in the regulatory cross-talk between these two metabolic tissues. SENP2 induces de-SUMOylation of PPAR α which promotes its ubiquitylation and subsequent degradation, causing a significant downregulation of FGF21. SENP2 also exerts control over adipogenesis and adipose lipid storage in different manners⁸¹. Similarly, SENP3 was predominantly up-regulated in MASLD patients and HFD fed rats. Up-regulated lipid accumulation with FFA treatment was markedly ameliorated with SENP3-siRNA transfection and this conclusion should be further verified in animal models⁸².

Compromised SUMOylation of liver receptor homolog-1 (LRH-1) induced the expression of oxysterol binding protein-like 3 (OSBPL3), thus enhancing SREBP1 procession and promoting the development of MASLD⁸³. In another case, SUMO2

modification of farnesoid X receptor (FXR) at K277 increased the interaction with NF- κ B and decreased the binding of retinoid X receptor alpha (RXR α). FXR modified by SUMO2 repressed NF- κ B target inflammatory genes but it didn't affect the FXR/RXR α target genes. In diet-induced obese mice, FXR was highly acetylated and inhibited SUMO2 modification, leading to the transactivation of inflammatory genes⁸⁴. SUMO E3 ligase PIASy induced SREBP1c SUMOylation and increased its proteasome degradation, ultimately leading to a reduction in hepatic lipogenesis when fasting or nutritional deprivation⁸⁵. Prospero homeobox 1 (PROX1), a key transcriptional regulator of lipid metabolism, is SUMOylated on lysine residue 556, thus affecting its ability to regulate cholesterol metabolism transcription. The hepatocyte-selective loss of SUMOylation on PROX1 reduces systemic cholesterol levels⁸⁶.

5. NEDDylation and MASLD

Neddylation is a reversible post-translational modification process that involves attaching the ubiquitin-like protein, NEDD8, to a target protein. This process is catalyzed by a cascade of NEDD8-activating enzyme (NAE), NEDD8 binding enzyme (UBE2M/UBE2F), and NEDD8 ligase^{87,88}. Studies have found that serum NEDD8 levels were positively associated with the severity of MASLD in patients and pre-clinical mouse models. And MLN4924, a neddylation inhibitor, could boost fatty acid oxidation and reduce hepatic steatosis in pre-clinical mouse models. This suggested that neddylation is an effective intervention for MASLD^{89–91}. Cullin-associated and neddylation-dissociated protein 1 (CAND1) also alleviated MASLD by reducing ubiquitinated degradation of acetyl-CoA acyltransferase 2 (ACAA2)⁹². Neddylation of multiple substrate proteins has been reported to influence disease progression in MASLD, such as serine-rich splicing factor 3 (SRSF3), SREBP1c and DEP-domain containing mTOR-interacting protein (DEPTOR). For instance, the neddylation of SRSF3 was found to be crucial for its proteasomal degradation, and inhibition of SRSF3 neddylation could inhibit the MASH progression⁹³. Neddylation inhibition increased DEPTOR content and repressed the mTOR signaling, which resulted in enhanced fatty acid oxidation and reduced liver lipid accumulation⁸⁹. Additionally, inhibition of Cullin neddylation was found to reduce IRS degradation, thereby enhancing hepatic insulin signaling and reducing hepatic glucose production⁹⁴. And neddylation of SREBP1c has been reported to compete with ubiquitination, thereby stabilizing its

Table 4 Pathophysiological roles of SUMOylation and NEDDylation in MASLD.

The modified protein	Enzyme	Ubiquitin-like modification type	Regulating effect	Inhibit/Promote NAFLD/NASH	Ref.
RIPK1	SENP1	deSUMOylation	Activity ↓	Inhibit	79
	PIAS1	SUMOylation	Activity ↑	Promote	79
Sharp-1	SENP1	deSUMOylation	Activity ↓	Promote	80
PPAR α	SENP2	deSUMOylation	Degradation ↑	Promote	81
LRH-1	—	SUMOylation	Transcription function ↑	Inhibit	83
FXR	PIASy	SUMOylation	Transcription of NF- κ B ↓	Inhibit	84
SREBP1c	PIASy	SUMOylation	Transcription function ↑/↓	Inhibit	85
Prox1	—	SUMOylation	Transcription function ↑/↓	Promote	86
SRSF3	—	NEDDylation	Degradation ↑	Promote	93
DEPTOR	—	NEDDylation	Degradation ↑	Promote	89
SREBP1c	HDM2	NEDDylation	Degradation ↓	Promote	90
Cullin	—	NEDDylation	IRS degradation ↑	Promote	94

protein level and promoting hepatic steatosis⁹⁰. Existing evidence suggests that inhibition of neddylation is a potential treatment strategy for MASLD and this highlights the need for further research to fully elucidate the complex roles of neddylation in the pathogenesis and progression of MASLD (Table 4).

6. Targeting UPS for MASLD treatment

Inhibitors targeting the UPS have shown promising potential in the context of MASLD. There are two main mechanisms of action of these inhibitors: (1) targeting enzymes in the UPS system that function in MASLD and (2) promoting or inhibiting the proteasome degradation of specific proteins that either promote or inhibit the disease (Table 5^{36,68,90,91,96-101}). The N-terminus (S1) and C-terminus (S3) of FBXW5 respectively and competitively ablate the function of FBXW5, activating ASK1 and thus blocking ASK1-c-Jun/P38 MAPK signaling³⁶. P22077, a selective USP7 inhibitor, inhibited pathological hepatic *de novo* lipogenesis by disturbing the USP7/ZNF638 axis⁶⁸. USP1 inhibitor ML323 prevented adipogenesis and lipid accumulation by decreasing C/EBP β protein stability and increasing its ubiquitination⁹⁵. The regulatory particle non-ATPase 11 (RPN11) inhibitor capzimin inhibited the RPN11–METTL3–ACSS3 axis and downregulated lipid-related genes⁹⁶. Neddylation inhibitor MLN4924 and SUMOylation inhibitor SP have also shown potential in inhibiting MASLD progression^{90,91,97}. MLN4924 reduces excess lipid storage by stimulating fatty acid oxidation and lipid metabolites in liver mitochondria. SUMOylation inhibitors restore FXR signaling, and coadministration with FXR agonists drastically impeded MASH-induced fibrosis. 4-Azidophlorizin promoted the ubiquitin proteasome degradation of geranylgeranyl diphosphate synthase (GGPPS), thus alleviating hepatic steatosis⁹⁸. Similarly, thiolutin (THL), an inhibitor of the JAB1/MPN/Mov34 (JAMM) domain, could potentially inhibit NOD-like receptor protein 3 (NLRP3) deubiquitination and inflammasome activation in the model of diet-induced nonalcoholic fatty liver disease⁹⁹. Corylinan, an HSP90 β -selective inhibitor, inhibited *de novo* lipid synthesis by promoting mSREBPs ubiquitination and proteasomal degradation¹⁰⁰. And PROTACI-d promoted the degradation of Keap1 to alleviate oxidative stress and MASLD¹⁰¹.

7. Conclusions and prospects

Ubiquitination modification of the P38 MAPK signal pathway has been extensively reported in MASLD (Fig. 3). P38 MAPK participates in the progression of MASLD. Oxidative stress and inflammation activate the hepatic P38 MAPK signal pathway,

leading to insulin resistance and impairs lipid metabolism¹⁰². Both ASK1 and TAK1 are significant upstream kinases of P38 MAPK and their activity is largely regulated by ubiquitination. The activity of ASK1 is negatively regulated by deubiquitinases OTUB1 and TNFAIP3 while E3 ligases FBXW5 and TRAF6 promote ASK1 activation. Analogously, DUBs CYLD, USP14 and USP18 inactive TAK1 while E3 ligase TRAF3 activates TAK. Therefore, considering using the P38 MAPK signaling pathway as the therapeutic target for MASLD, inhibition of associated E3 ligase may be an effective strategy while the DUBs involved play a protective role in MASLD.

Additionally, the role of ubiquitin and ubiquitin-like modifications as either protective mechanisms or contributors to disease progression remains ambiguous due to the complexities of these post-translational modifications. Enzymes like FBXW7, Smurf1, USP7, and USP22 have been reported to have differing impacts on disease advancement within different contexts. This inconsistency is largely due to variations in the substrate proteins these enzymes interact with. For instance, USP22's contradictory role in MASLD progression is mainly due to the difference in the substrate: when interacting with PPAR γ , it promotes disease progression, but when in connection with Sirt1, it has an inhibitory effect. In addition to this, tissue-specific expression of proteins contributes to the functional disparities.

The UPS systems members participating in MASLD development mentioned above were mostly researched in liver parenchymal cells. Only a few studies have shown that UPS systems play a role in regulating MASLD in other cell types, such as macrophages and adipose tissue. STIP1 homology and U-Box containing protein 1 (STUB1) in adipocytes promoted the degradation of nuclear receptor subfamily 2 group F member 2 (NR2F2) and the transcription of adiponectin (APN), thus alleviating liver steatosis and hepatic stellate cells activation¹⁰³. USP19 also modulated adipogenesis and potentiated high-fat-diet-induced obesity and glucose intolerance¹⁰⁴. Macrophage USP2A significantly improved insulin sensitivity and prevented age- and/or adiposity-related chronic inflammation, although the mechanism is unclear¹⁰⁵. Undeniably, macrophages, adipose tissue and hepatic stellate cells play an important role in the pathological process of MASLD, but the function of the UPS system in these scenarios remains unclear. Therefore, the multi-omics approach is essential to fully elucidate the functions of ubiquitination and ubiquitin-like modifications in MASLD, these techniques can reveal new significant proteins that regulate disease progression and shed more light on the ubiquitination system's role in MASLD.

Along with the insight into the role of the ubiquitination system in various stages of liver disease has become a growing point of interest, increasing studies have found that the same protein plays

Table 5 Small-molecule inhibitors targeting UPS systems in MASLD.

Inhibitor name	Target molecular	Inhibition molecular	Ref.
S1 or S3 of FBXW5	FBXW5	Competitively ablating the function of FBXW5 on ASK1 activation	36
P22077	USP7	Inhibiting DNL by the inhibition of ZNF638	68
ML323	USP1	Decreasing C/EBP β protein stability and increasing its ubiquitination	—
Capzimin	RPN11	Inhibiting RPN11–METTL3–ACSS3 axis and downregulating lipid-related genes	96
MLN4924	NEDDylation	Inhibiting the NEDDylation and reducing the levels of SREBP1c	90,91
SP	SUMOylation	Restoring FXR activity and function	97,101
PROTACI-d	Keap1	Promoting the degradation of Keap1 to alleviate oxidative stress and MASLD	101
4-Azidophlorizin	GGPPS	Promoting the degradation of GGPPS by the ubiquitin–proteasome pathway	98
Corylin	HSP90 β	Promoting mSREBPs degradation through Akt–GSK3 β –FBW7 pathway	100
Thiolutin (THL)	NLRP3	Inhibiting NLRP3 deubiquitination and activation	99




Figure 3 The P38 MAPK signaling pathway is regulated by ubiquitination in MASLD. FBXW5 and TRAF6 stimulate ASK1 activation by increasing ubiquitination and activation could be inhibited by OTUB1 and TNFAIP3. Similarly, TAK1 is activated by TRAF3 and deactivated by CYLD, USP4 and USP18. TRIM38 and TRIM16 promote the ubiquitination degradation of TAB2 and TAK1 respectively. And TRAF5 promotes JAK1 inactivation, resulting in inhibition of the P38 MAPK signaling pathway.

opposite functions in different stages of liver disease. USP10 protects the liver from MASLD but promotes metastasis of HCC in advanced stages of the disease^{58,106}. As MASLD is a progressive disease that will eventually progress to HCC, it seems contradictory to play different pathological roles in MASLD and HCC. The underlying reasons may be attributed to the complex pathogenesis of HCC and the substrate selectivity of E3 ligase and DUB under

different pathological conditions, and this suggests that elucidating the role of ubiquitin and ubiquitin-like modifications in hepatic diseases remains challenging. In this review, we proposed that ubiquitin and ubiquitin-like modifications play a crucial role in liver lipid metabolism and glucose metabolism and are deregulated significantly under pathological. We also summarized the expression levels of UPS-related




Figure 4 Expression levels of UPS-related proteins in MASLD. The black font represents E3 ubiquitin ligases; The red represents deubiquitinating enzymes and the green represents the SUMO-specific proteases.

proteins in MASLD patients compared to healthy controls (Fig. 4). Given that the regulators of these processes are mostly enzymes, which are more accessible to be targeted by small molecules with high specificity, targeting ubiquitin and ubiquitin-like modification processes may be an effective therapeutic strategy for MASLD. However, several scientific challenges remain in the development of drugs targeting ubiquitin signaling for MASLD. First, the selectivity of these inhibitors remains to be improved, hampering their clinical application. Additionally, research is needed to accurately target the liver to avoid organ toxicity, as the tissue distribution of the target proteins lacks specificity. Furthermore, identifying appropriate biomarkers is critical to determine suitable application scenarios for these inhibitors. Considering that the liver is a key organ for metabolism and that this process heavily relies on mitochondria for energy, enhancing mitochondrial function presents an effective strategy for treating liver diseases. This underscores the importance and feasibility of targeting organelles. Moreover, the endoplasmic reticulum is an essential site for protein synthesis and the clearance of misfolded proteins, playing a crucial role in maintaining protein homeostasis. Therefore, focusing on protein homeostasis within the endoplasmic reticulum could provide more effective targeting strategies for the treatment of MASLD.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant Nos. U21A20420, 82373895 and 82304517) and the Zhejiang Provincial Natural Science Foundation (Grant No. LQ23H310009, China).

Author contributions

Yue Liu: Writing – review & editing, Writing – original draft, Visualization, Investigation, Conceptualization. Meijia Qian: Writing – review & editing, Writing – original draft, Visualization, Investigation. Yonghao Li: Investigation. Xin Dong: Investigation. Yulian Wu: Writing – review & editing. Tao Yuan: Writing – review & editing, Project administration, Investigation, Funding acquisition, Conceptualization. Jian Ma: Investigation. Bo Yang: Writing – review & editing, Supervision, Project administration, Investigation, Funding acquisition, Conceptualization. Hong Zhu: Writing – review & editing, Writing – original draft, Visualization, Supervision, Project administration, Investigation, Funding acquisition, Conceptualization. Qiaojun He: Writing – review & editing, Supervision, Project administration, Investigation, Funding acquisition, Conceptualization.

Conflicts of interest

The authors declare that they have no competing interests.

References

- Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. *J Hepatol* 2023;**79**:842–52.
- Zhu Y, Liu H, Zhang M, Guo GL. Fatty liver diseases, bile acids, and FXR. *Acta Pharm Sin B* 2016;**6**:409–12.
- Marchesini G, Vettor R, Pinzani M. MASLD emerging from the fog of fatty liver. *J Hepatol* 2024;**80**:178–80.
- Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). *Cell Mol Life Sci* 2019;**76**:1541–58.
- Coyne ES, Bédard N, Gong YJ, Faraj M, Tchernof A, Wing SS. The deubiquitinating enzyme USP19 modulates adipogenesis and potentiates high-fat-diet-induced obesity and glucose intolerance in mice. *Diabetologia* 2019;**62**:136–46.
- Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. *Hepatol Int* 2020;**14**:8–23.
- Park J, Cho J, Song EJ. Ubiquitin–proteasome system (UPS) as a target for anticancer treatment. *Arch Pharm Res (Seoul)* 2020;**43**:1144–61.
- Yuan T, Yan F, Ying M, Cao J, He Q, Zhu H, et al. Inhibition of ubiquitin-specific proteases as a novel anticancer therapeutic strategy. *Front Pharmacol* 2018;**9**:1080.
- Eldridge AG, O'Brien T. Therapeutic strategies within the ubiquitin proteasome system. *Cell Death Differ* 2010;**17**:4–13.
- Jiang Y, Ni S, Xiao B, Jia L. Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy. *Acta Pharm Sin B* 2023;**13**:4341–72.
- Park JS, Ma H, Roh YS. Ubiquitin pathways regulate the pathogenesis of chronic liver disease. *Biochem Pharmacol* 2021;**193**:114764.
- Xia SW, Wang ZM, Sun SM, Su Y, Li ZH, Shao JJ, et al. Endoplasmic reticulum stress and protein degradation in chronic liver disease. *Pharmacol Res* 2020;**161**:105218.
- Yang Q, Zhao J, Chen D, Wang Y. E3 ubiquitin ligases: styles, structures and functions. *Mol Biomed* 2021;**2**:23.
- Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases. *Nat Rev Mol Cell Biol* 2009;**10**:398–409.
- Wang L, Zhang X, Lin ZB, Yang PJ, Xu H, Duan JL, et al. Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1. *Cell Metab* 2021;**33**:1372–88.e7.
- Xu MX, Tan J, Ge CX, Dong W, Zhang LT, Zhu LC, et al. Tripartite motif-containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen-activated protein kinase kinase 7. *Hepatology (Baltimore, Md)* 2023;**77**:124–43.
- Xu M, Tan J, Dong W, Zou B, Teng X, Zhu L, et al. The E3 ubiquitin–protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes. *Nat Commun* 2022;**13**:1052.
- Hu Y, He W, Huang Y, Xiang H, Guo J, Che Y, et al. Fatty acid synthase-suppressor screening identifies sorting Nexin 8 as a therapeutic target for NAFLD. *Hepatology* 2021;**74**:2508–25.
- Kettunen KM, Karikoski R, Hämmäläinen RH, Toivonen TT, Anttonenkov VD, Kuleshkaya N, et al. Trim37-deficient mice recapitulate several features of the multi-organ disorder Mulibrey nanism. *Biol Open* 2016;**5**:584–95.
- Yao X, Dong R, Hu S, Liu Z, Cui J, Hu F, et al. Tripartite motif 38 alleviates the pathological process of NAFLD–NASH by promoting TAB2 degradation. *J Lipid Res* 2023;**64**:100382.
- Xu M, Tan J, Liu X, Han L, Ge C, Zhang Y, et al. Tripartite motif containing 26 prevents steatohepatitis progression by suppressing C/EBP δ signalling activation. *Nat Commun* 2023;**14**:6384.
- Yu Q, Xia Z, Liong EC, Tipoe GL. Chronic aerobic exercise improves insulin sensitivity and modulates Nrf2 and NF- κ B/ $\text{I}\kappa$ B α pathways in the skeletal muscle of rats fed with a high fat diet. *Mol Med Rep* 2019;**20**:4963–72.
- Gao L, Wang PX, Zhang Y, Yu CJ, Ji Y, Wang X, et al. Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis. *J Hepatol* 2016;**65**:125–36.
- Lin Z, Yang P, Hu Y, Xu H, Duan J, He F, et al. RING finger protein 13 protects against nonalcoholic steatohepatitis by targeting STING-relayed signaling pathways. *Nat Commun* 2023;**14**:6635.
- Yang X, Sun D, Xiang H, Wang S, Huang Y, Li L, et al. Hepatocyte SH3RF2 deficiency is a key aggravator for NAFLD. *Hepatology (Baltimore, Md)* 2021;**74**:1319–38.

26. Yang Q, Chen X, Zhang Y, Hu S, Hu F, Huang Y, et al. The E3 ubiquitin ligase ring finger protein 5 ameliorates NASH through ubiquitin-mediated degradation of 3-hydroxy-3-methylglutaryl CoA reductase degradation protein 1. *Hepatology (Baltimore, Md)* 2021; **74**:3018–36.
27. Li K, Zhang K, Wang H, Wu Y, Chen N, Chen J, et al. Hrd1-mediated ACLY ubiquitination alleviate NAFLD in *db/db* mice. *Metabolism* 2021; **114**:154349.
28. Zhang T, Kho DH, Wang Y, Harazono Y, Nakajima K, Xie Y, et al. Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer. *PLoS One* 2015; **10**:e0118448.
29. Zhang Y, Lin S, Peng J, Liang X, Yang Q, Bai X, et al. Amelioration of hepatic steatosis by dietary essential amino acid-induced ubiquitination. *Mol Cell* 2022; **82**:1528–42.e10.
30. Huang C, Wei X, Luo Q, Xia Y, Pan T, He J, et al. Loss of TRIM67 attenuates the progress of obesity-induced non-alcoholic fatty liver disease. *Int J Mol Sci* 2022; **23**:7475.
31. Zhang J, Xie H, Yao J, Jin W, Pan H, Pan Z, et al. TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination. *Hum Cell* 2023; **36**:209–22.
32. Chen Z, Canet MJ, Sheng L, Jiang L, Xiong Y, Yin L, et al. Hepatocyte TRAF3 promotes insulin resistance and type 2 diabetes in mice with obesity. *Mol Metab* 2015; **4**:951–60.
33. Zhang JL, Du BB, Zhang DH, Li H, Kong LY, Fan GJ, et al. OTUB1 alleviates NASH through inhibition of the TRAF6–ASK1 signaling pathways. *Hepatology (Baltimore, Md)* 2022; **75**:1218–34.
34. Lee MS, Han HJ, Han SY, Kim IY, Chae S, Lee CS, et al. Loss of the E3 ubiquitin ligase MKRN1 represses diet-induced metabolic syndrome through AMPK activation. *Nat Commun* 2018; **9**:3404.
35. Liu PY, Chen CC, Chin CY, Liu TJ, Tsai WC, Chou JL, et al. E3 ubiquitin ligase Grail promotes hepatic steatosis through Sirt1 inhibition. *Cell Death Dis* 2021; **12**:323.
36. Bai L, Chen MM, Chen ZD, Zhang P, Tian S, Zhang Y, et al. F-box/WD repeat-containing protein 5 mediates the ubiquitination of apoptosis signal-regulating kinase 1 and exacerbates nonalcoholic steatohepatitis in mice. *Hepatology (Baltimore, Md)* 2019; **70**:1942–57.
37. Xia H, Dufour CR, Medkour Y, Scholtes C, Chen Y, Guluzian C, et al. Hepatocyte FBXW7-dependent activity of nutrient-sensing nuclear receptors controls systemic energy homeostasis and NASH progression in male mice. *Nat Commun* 2023; **14**:6982.
38. Zhang C, Chen F, Feng L, Shan Q, Zheng GH, Wang YJ, et al. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease. *Mol Med* 2019; **25**:29.
39. Zhu K, Tang Y, Xu X, Dang H, Tang LY, Wang X, et al. Non-proteolytic ubiquitin modification of PPAR γ by Smurf1 protects the liver from steatosis. *PLoS Biol* 2018; **16**:e3000091.
40. Zhang X, Zhan Y, Lin W, Zhao F, Guo C, Chen Y, et al. Smurf1 aggravates non-alcoholic fatty liver disease by stabilizing SREBP-1c in an E3 activity-independent manner. *FASEB J* 2020; **34**:7631–43.
41. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. *Annu Rev Biochem* 2009; **78**:399–434.
42. Hatakeyama S. TRIM proteins and cancer. *Nat Rev Cancer* 2011; **11**:792–804.
43. Chen Z, Sheng L, Shen H, Zhao Y, Wang S, Brink R, et al. Hepatic TRAF2 regulates glucose metabolism through enhancing glucagon responses. *Diabetes* 2012; **61**:566–73.
44. Joshi V, Upadhyay A, Kumar A, Mishra A. Gp78 E3 ubiquitin ligase: essential functions and contributions in proteostasis. *Front Cell Neurosci* 2017; **11**:259.
45. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW, et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). *Cell Metab* 2005; **1**:379–91.
46. Zhao X, Hirota T, Han X, Cho H, Chong LW, Lamia K, et al. Circadian amplitude regulation via FBXW7-targeted REV-ERB α degradation. *Cell* 2016; **165**:1644–57.
47. Park JH, Kang HJ, Lee YK, Kang H, Kim J, Chung JH, et al. Inactivation of EWS reduces PGC-1 α protein stability and mitochondrial homeostasis. *Proc Natl Acad Sci U S A* 2015; **112**:6074–9.
48. Ma N, Wang YK, Xu S, Ni QZ, Zheng QW, Zhu B, et al. PDPF alleviates hepatic steatosis through inhibition of mTOR signaling. *Nat Commun* 2021; **12**:3059.
49. Zhu K, Tang Y, Xu X, Dang H, Tang LY, Wang X, et al. Non-proteolytic ubiquitin modification of PPAR γ by Smurf1 protects the liver from steatosis. *PLoS Biol* 2018; **16**:e3000091.
50. Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. *Annu Rev Biochem* 2017; **86**:159–92.
51. D'Arcy P, Wang X, Linder S. Deubiquitinase inhibition as a cancer therapeutic strategy. *Pharmacol Ther* 2015; **147**:32–54.
52. Lange SM, Armstrong LA, Kulathu Y. Deubiquitinases: from mechanisms to their inhibition by small molecules. *Mol Cell* 2022; **82**:15–29.
53. Ji YX, Huang Z, Yang X, Wang X, Zhao LP, Wang PX, et al. The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. *Nat Med* 2018; **24**:213–23.
54. Zhao Y, Wang F, Gao L, Xu L, Tong R, Lin N, et al. Ubiquitin-specific protease 4 is an endogenous negative regulator of metabolic dysfunctions in nonalcoholic fatty liver disease in mice. *Hepatology (Baltimore, Md)* 2018; **68**:897–917.
55. Zhang DG, Kunz WS, Lei XJ, Zito E, Zhao T, Xu YC, et al. Selenium ameliorated oxidized fish oil-induced lipotoxicity via the inhibition of mitochondrial oxidative stress, remodeling of Usp4-mediated deubiquitination and stabilization of Ppar α . *Antioxid Redox Signal* 2024; **40**:433–52.
56. An S, Zhao LP, Shen LJ, Wang S, Zhang K, Qi Y, et al. USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity. *Hepatology (Baltimore, Md)* 2017; **66**:1866–84.
57. Xu M, Tan J, Zhu L, Ge C, Dong W, Dai X, et al. The deubiquitinating enzyme 13 retards non-alcoholic steatohepatitis via blocking inactive rhomboid protein 2-dependent pathway. *Acta Pharm Sin B* 2023; **13**:1071–92.
58. Luo P, Qin C, Zhu L, Fang C, Zhang Y, Zhang H, et al. Ubiquitin-specific peptidase 10 (USP10) inhibits hepatic steatosis, insulin resistance, and inflammation through Sirt6. *Hepatology (Baltimore, Md)* 2018; **68**:1786–803.
59. Zhou N, Qi H, Liu J, Zhang G, Liu J, Liu N, et al. Deubiquitinase OTUD3 regulates metabolism homeostasis in response to nutritional stresses. *Cell Metab* 2022; **34**:1023–41.e8.
60. Zhang P, Wang PX, Zhao LP, Zhang X, Ji YX, Zhang XJ, et al. The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. *Nat Med* 2018; **24**:84–94.
61. Verboom L, Martens A, Priem D, Hoste E, Sze M, Vikkula H, et al. OTULIN prevents liver inflammation and hepatocellular carcinoma by inhibiting FADD- and RIPK1 kinase-mediated hepatocyte apoptosis. *Cell Rep* 2020; **30**:2237–47.e6.
62. Liu B, Jiang S, Li M, Xiong X, Zhu M, Li D, et al. Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN. *Nat Commun* 2018; **9**:4770.
63. Lu XY, Shi XJ, Hu A, Wang JQ, Ding Y, Jiang W, et al. Feeding induces cholesterol biosynthesis via the mTORC1–USP20–HMGCR axis. *Nature* 2020; **588**:479–84.
64. Baek JH, Kim MS, Jung HR, Hwang MS, Lee CH, Han DH, et al. Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Exp Mol Med* 2023; **55**:1520–30.
65. Yang H, Park D, Ryu J, Park T. USP11 degrades KLF4 via its deubiquitinase activity in liver diseases. *J Cell Mol Med* 2021; **25**:6976–87.
66. Kim TH, Yang YM, Han CY, Koo JH, Oh H, Kim SS, et al. G α 12 ablation exacerbates liver steatosis and obesity by suppressing

- USP22/SIRT1-regulated mitochondrial respiration. *J Clin Invest* 2018;**128**:5587–602.
67. Ning Z, Guo X, Liu X, Lu C, Wang A, Wang X, et al. USP22 regulates lipidome accumulation by stabilizing PPAR γ in hepatocellular carcinoma. *Nat Commun* 2022;**13**:2187.
 68. Ni W, Lin S, Bian S, Zheng W, Qu L, Fan Y, et al. USP7 mediates pathological hepatic *de novo* lipogenesis through promoting stabilization and transcription of ZNF638. *Cell Death Dis* 2020;**11**:843.
 69. Forand A, Koumakis E, Rousseau A, Sassier Y, Journe C, Merlin JF, et al. Disruption of the phosphate transporter Pit1 in hepatocytes improves glucose metabolism and insulin signaling by modulating the USP7/IRS1 interaction. *Cell Rep* 2016;**16**:2736–48.
 70. Jiang L, Xiong J, Zhan J, Yuan F, Tang M, Zhang C, et al. Ubiquitin-specific peptidase 7 (USP7)-mediated deubiquitination of the histone deacetylase SIRT7 regulates gluconeogenesis. *J Biol Chem* 2017;**292**:13296–311.
 71. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. *Annu Rev Biochem* 2009;**78**:363–97.
 72. Xin SL, Yu YY. Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity. *Dig Liver Dis* 2022;**54**:1021–9.
 73. Xin SL, Pan XL, Xu XY, Yu YY. USP10 alleviates palmitic acid-induced steatosis through autophagy in HepG2 cells. *J Clin Transl Hepatol* 2023;**11**:45–57.
 74. Tao BB, He H, Shi XH, Wang CL, Li WQ, Li B, et al. Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade. *J Clin Neurosci* 2013;**20**:717–20.
 75. Chen Y, Xu X, Wang Y, Zhang Y, Zhou T, Jiang W, et al. Hypoxia-induced SKA3 promoted cholangiocarcinoma progression and chemoresistance by enhancing fatty acid synthesis via the regulation of PAR-dependent HIF-1 α deubiquitylation. *J Exp Clin Cancer Res* 2023;**42**:265.
 76. Hall JA, Tabata M, Rodgers JT, Puigserver P. USP7 attenuates hepatic gluconeogenesis through modulation of *FoxO1* gene promoter occupancy. *Mol Endocrinol* 2014;**28**:912–24.
 77. Du J, Fu L, Sui Y, Zhang L. The function and regulation of OTU deubiquitinases. *Front Med* 2020;**14**:542–63.
 78. Xie M, Yu J, Ge S, Huang J, Fan X. SUMOylation homeostasis in tumorigenesis. *Cancer Lett* 2020;**469**:301–9.
 79. Yan L, Zhang T, Wang K, Chen Z, Yang Y, Shan B, et al. SENP1 prevents steatohepatitis by suppressing RIPK1-driven apoptosis and inflammation. *Nat Commun* 2022;**13**:7153.
 80. Liu B, Wang T, Mei W, Li D, Cai R, Zuo Y, et al. Small ubiquitin-like modifier (SUMO) protein-specific protease 1 de-SUMOylates Sharp-1 protein and controls adipocyte differentiation. *J Biol Chem* 2014;**289**:22358–64.
 81. Liu Y, Dou X, Zhou WY, Ding M, Liu L, Du RQ, et al. Hepatic small ubiquitin-related modifier (SUMO)-specific protease 2 controls systemic metabolism through SUMOylation-dependent regulation of liver-adipose tissue crosstalk. *Hepatology (Baltimore, Md)* 2021;**74**:1864–83.
 82. Liu Y, Yu F, Han Y, Li Q, Cao Z, Xiang X, et al. SUMO-specific protease 3 is a key regulator for hepatic lipid metabolism in non-alcoholic fatty liver disease. *Sci Rep* 2016;**6**:37351.
 83. Stein S, Lemos V, Xu P, Demagny H, Wang X, Ryu D, et al. Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease. *J Clin Invest* 2017;**127**:583–92.
 84. Kim D-H, Xiao Z, Kwon S, Sun X, Ryerson D, Tkac D, et al. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. *EMBO J* 2015;**34**:184–99.
 85. Lee GY, Jang H, Lee JH, Huh JY, Choi S, Chung J, et al. PIASy-mediated sumoylation of SREBP1c regulates hepatic lipid metabolism upon fasting signaling. *Mol Cell Biol* 2014;**34**:926–38.
 86. Alfaro AJ, Dittner C, Becker J, Loft A, Mhamane A, Maida A, et al. Fasting-sensitive SUMO-switch on Prox1 controls hepatic cholesterol metabolism. *EMBO Rep* 2023;**24**:e55981.
 87. Zhou L, Jiang Y, Luo Q, Li L, Jia L. Neddylation: a novel modulator of the tumor microenvironment. *Mol Cancer* 2019;**18**:77.
 88. Enchev RI, Schulman BA, Peter M. Protein neddylation: beyond cullin-RING ligases. *Nat Rev Mol Cell Biol* 2015;**16**:30–44.
 89. Serrano-Maciá M, Simón J, González-Rellán MJ, Azkargorta M, Goikotxea-Usandizaga N, Lopitz-Otsoa F, et al. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR–mTOR axis. *Mol Metab* 2021;**53**:101275.
 90. Ju UI, Jeong DW, Seo J, Park JB, Park JW, Suh KS, et al. Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment. *Cell Death Dis* 2020;**11**:283.
 91. Ge M, Huang L, Ma Y, Sun S, Wu L, Xu W, et al. MLN4924 treatment diminishes excessive lipid storage in high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) by stimulating hepatic mitochondrial fatty acid oxidation and lipid metabolites. *Pharmaceutics* 2022;**14**:2460.
 92. Huang X, Liu X, Li X, Zhang Y, Gao J, Yang Y, et al. Cullin-associated and neddylation-dissociated protein 1 (CAND1) alleviates NAFLD by reducing ubiquitinated degradation of ACAA2. *Nat Commun* 2023;**14**:4620.
 93. Kumar D, Das M, Saucedo C, Ellies LG, Kuo K, Parwal P, et al. Degradation of splicing factor SRSF3 contributes to progressive liver disease. *J Clin Invest* 2019;**129**:4477–91.
 94. Chen C, Gu L, Matye DJ, Clayton YD, Hasan MN, Wang Y, et al. Cullin neddylation inhibitor attenuates hyperglycemia by enhancing hepatic insulin signaling through insulin receptor substrate stabilization. *Proc Natl Acad Sci U S A* 2022;**119**:e2111737119.
 95. Kim MS, Baek JH, Lee J, Sivaraman A, Lee K, Chun KH. Deubiquitinase USP1 enhances CCAAT/enhancer-binding protein beta (C/EBP β) stability and accelerates adipogenesis and lipid accumulation. *Cell Death Dis* 2023;**14**:776.
 96. Zhou B, Luo Y, Bi H, Zhang N, Ma M, Dong Z, et al. Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11. *Cell Metab* 2024;**36**:2228-44.e7.
 97. Zhou J, Cui S, He Q, Guo Y, Pan X, Zhang P, et al. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. *Nat Commun* 2020;**11**:240.
 98. Ye J, Qi Y, Chen J, Zhang S, Liu B, Zhao Y, et al. Alleviation of hepatic steatosis by 4-azidophlorizin via the degradation of geranylgeranyl diphosphate synthase by the ubiquitin–proteasome pathway *in vivo* and *in vitro*. *Adv Biol* 2023;**7**:e2200150.
 99. Ren GM, Li J, Zhang XC, Wang Y, Xiao Y, Zhang XY, et al. Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases. *Sci Immunol* 2021;**6**:eabe2933.
 100. Zheng ZG, Zhang X, Liu XX, Jin XX, Dai L, Cheng HM, et al. Inhibition of HSP90 β improves lipid disorders by promoting mature SREBPs degradation via the ubiquitin–proteasome system. *Theranostics* 2019;**9**:5769–83.
 101. Qi M, Zhong H, Cheng Z, Chen S, Xiao H, Shang J, et al. Discovery of NAFLD-improving agents by promoting the degradation of Keap1. *J Med Chem* 2023;**66**:9184–200.
 102. Lawan A, Bennett AM. Mitogen-activated protein kinase regulation in hepatic metabolism. *Trends Endocrinol Metab* 2017;**28**:868–78.
 103. Mao Z, Zhao J, Cui F, Li Z, Cao J, Zhou J, et al. STUB1 increases adiponectin expression by inducing ubiquitination and degradation of NR2F2, thereby reducing hepatic stellate cell activation and alleviating non-alcoholic fatty liver disease. *Tissue Cell* 2024;**88**:102345.
 104. Coyne ES, Bédard N, Gong YJ, Faraj M, Tchernof A, Wing SS. The deubiquitinating enzyme USP19 modulates adipogenesis and potentiates high-fat-diet-induced obesity and glucose intolerance in mice. *Diabetologia* 2019;**62**:136–46.
 105. Saito N, Kimura S, Miyamoto T, Fukushima S, Amagasa M, Shimamoto Y, et al. Macrophage ubiquitin-specific protease 2 modifies insulin sensitivity in obese mice. *Biochem Biophys Rep* 2017;**9**:322–9.
 106. Yuan T, Chen Z, Yan F, Qian M, Luo H, Ye S, et al. Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein. *Mol Oncol* 2020;**14**:197–210.